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IT was previously postulated (Currie and Bagshawe 1967) that cell wall
sialomucins might mask tumour-cell antigens and thus inhibit the host's immuno-
logical mechanisms by preventing antigen detection. The use of neuraminidase
to disrupt cell wall sialomucins and thus to unmask the antigenicity of experi-
mental tumours has recently been described (Currie, 1967; Sandford, 1967) and
lends support to the antigen masking hypothesis.
This report describes experiments designed to examine the mode of action of
neuraminidase in inducing immunity against a non-specific transplantable tumour.
MATERIALS AND METHODS
Tumouor
The Landschutz ascites tumour was grown in adult male A2G mice weighing
between 20 and 25 g. The tumour was serially passaged every 7 days by intra-
peritoneal injection of 0 2 ml. of undiluted ascites fluid. All experimental mice
in this series were similar adult A2G males randomly arranged in groups ofsix.
Neuraaminidase
The enzyme preparation used in these experiments wvas a purified filtrate from
cultures of Vibrio cholerae. It was supplied in an acetate buffer at pH 5*5 con-
taining calcium ions and had a quoted strength of 500 units/ml. (Behringwerke).
Treatment of tumour cells
Ascites fluid was withdrawn from a mouse 7 days after inoculation with tumour,
spun down gently and washed 5 timnes in Hanks Balanced Salt Solution (HBSS).
Tumour cells were incubated in either acetate buffer, in 500 units/ml. neuramini-
dase, or in neuraminidase previously heated to 600 C. for 30 minutes. The cells
were incubated at 370 C. for 30 minutes and then washed again 5 times in HBSS.
Tumour cell viability was assessed by lissamine green exclusion before and after
incubation. The cells were then administered to 3 groups of mice. Each mouse
received 4 x 106 tumour cells intraperitoneally and was observed for 60 days or
until death occurred.
Hydrocortisone treated mice
Two groups of mice were given daily subcutaneous injections ofhydrocortisone
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days they were given 3 mg. each and 1 mg. per day thereafter. On the third day
1 group received intraperitoneal neuraminidase-treated tumour cells and the
remaining group were given untreated cells which had been incubated in the acetate
buffer.
Attempted immunization of mice
Spleen cells were obtained by filtering the chopped and minced spleens from
6 adult male A2G mice. These cells were washed in HBSS. Half of them were
then incubated in 500 units/ml. neuraminidase for 30 minutes at 370 C. The
supernatant was retained and the cells washed 5 times in HBSS. Landschutz
ascites tumour cells were similarly treated and the supernatant retained. The
recipient mice were divided into 7 groups and received one of the following intra-
peritonea] injections: 4 x 106 neuraminidase-treated tumour cells, 0)2 ml.
treated tumour cell supernatant, 02 ml. neuraminidase solution (500 units/ml.),
0*2 ml. HBSS, 4 x 106 neuraminidase-treated A2G spleen cells, 0-2 ml. treated
spleen cell supernatant, 4 x 106 A2G spleen cells. All cell suspensions were
administered in 0-2 ml. HBSS. These mice were left for 14 days and then challen-
ged by the intraperitoneal administration of 5 x 104 Landschutz ascites tumour
cells per mouse. They were examined daily for the development of tumour.
Rechallenge
All mice which survived the intraperitoneal administration oftreated cells and
were clinically tumour free at 30 days were rechallenged by the intraperitoneal
injection of 5 x 104 tumour cells (5000 x LD50 for this tumour) and observed for
tumour development.
Mouse sera
Mice which survived tumour inoculation and control mice which were succum-
bing to tumour were bled by cardiac puncture and their sera separated and stored
at -20° C. These sera were assayed for anti-tumour agglutinins using the slide
technique described by Lindenmann (1964).
Adsorption of antiserum
0 5 ml. Aliquots of a 1: 5 dilution high agglutinin antiserum were adsorbed
by incubation for 1 hr with 20 x 106 tumour cells either neuraminidase-treated or
untreated. After incubation the cells were separated by centrifugation and the
supernatant antiserum re-assayed for agglutinins. Unadsorbed antiserum was
assayed at the same time.
RESULTS
Viability of cells as judged by dye exclusion was approximately 85 per cent and
was unaltered by incubation in neuraminidase or any ofthe control solutions.
The results are summarized in Tables I and II. Untreated tumour cells caused
massive ascites in all injected control animals. Death occurred approximately
16 days after inoculation and was associated with respiratory distress and
hypothermia. Haemoperitoneum was unusual in A2G mice but had been
common in previous experiments using adult male CBA mice.
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TABLE I.-The Effect of Incubation of LandschUitz Ascites Tumour Cells in Neura-
minidase and Heat-Inactivated Neuraminidase on the Subsequent Development
ofTumour in Normal and Hydrocortisone Treated Mice. Results are Expressed
as Number of Mice Surviving After 30 days/number of Mice Injected.
Treatment of recipient mice
Treatment of Tumour Cells Nil Hydrocortisone
Nil . 0/6 0/6
500 units/ml. Neuraminidase . 6/6 0/6
Rechallenged*
6/6
Heated neuraminidase . 0/6
500 units/ml.
* Animals rechallenged after 30 days with 5 x 104 tumour cells. Result expressed as survival
after another 30 days.
TABLE II.-The Effects ofPre-Exposure ofMice to Neuraminidase, Neuraminidase-
Treated Tumour Cells, Treated Spleen Cells, Untreated Spleen Cells and their
Supernatant Fluids on a Subsequent Challenge (14 days later) with 5 x 104
Landschutz Ascites Tumour Cells. Results are Expressed as Number of Mice
Surviving After 30 days/number of Mice Injected.
Result of challenge with 5 x 104
Intraperitoneal injection tumour cells
Neuraminidase treated tumour cells . 6/6 Rechallenged 6/6*
Treated tumour cell supernatant . 0/6
Neuraminidase only . 0/6
Neuraminidase treated A2G spleen cells . 0/6
Treated spleen cell supernatant . 0/6
Untreated A2G spleen cells . 0/6
HBSS . 0/6
* Animals rechallenged after 30 days with 5 X 104 tur.our cells. Result expressed as survival
after another 30 days.
Effect of neuraminidase on tumour development
Mice receiving cells treated in acetate buffer only, all developed tumour and
died at about Day 16. All animals which received neuraminidase-treated tumour
cells remained tumour free at 60 days. Rechallenge of animals with 5000 LD50
untreated tumour cells resulted in no tumour growth. Sacrifice and subsequent
dissection ofthese animals revealed no evidence oftumour, either solid or ascitic.
Tumour cells incubated in previously heated neuraminidase produced tumour
in all inoculated animals. Thus the effect ofneuraminidase on the tumour cells is
abolished byheating to 600 C. for 30minutes.
Hydrocortisone-treated mice
When neuraminidase-treated tumour cells were injected into hydrocortisone-
treated mice tumour developed in all recipients (Table I). The mean survival of
these animals after inoculation was approximately 23 days as was the survival of
hydrocortisone-treated mice given untreated tumour cells. Thus hydrocortisone
treatment of the host mice abolished the effect of neuraminidase on the tumour.
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Anti-tumouragglutinins
Using the slide agglutination technique powerful agglutinating activity was
detected in the sera of all surviving mice. Titres as high as 1: 5,120 were
detected. In control animals no agglutinins were detected above 1: 8.
Adsorption of antisera
The unadsorbed antiserum gave an agglutination titre of 1: 1600. After
adsorption for 1 hour with untreated tumour cells this titre fell to 1: 200. Ad-
sorption of the antiserum with an identical number of neuraminidase-treated
tumour cells produced an identical fall in titre to 1: 200. This indicates that
neuraminidase treatment ofthe tumour cells did not modify their ability to adsorb
agglutinins.
"Immunization " experiments
The results from this group of experiments are shown in Table II. A pro-
tective effect against subsequent challenge with untreated tumour cells could only
be produced by inoculation of neuraminidase-treated washed tumour cells.
Treated tumour cell supernatant, neuraminidase alone, HBSS, treated spleen cells
and the supernatant from these cells produced no effect, indicating that neura-
minidase induces tumour immunity by its effect on intact tumour cells.
DISCUSSION
The effect of neuraminidase on the immunogenicity of tumour cells is poorly
understood. There are many possible explanations of this phenomenon. The
results of the present study, however, indicate that most of these are untenable.
Release ofimmunogenic molecules
Lindenmann and Klein (1967) have suggested that neuraminidase acts by
releasing immunogenic molecules from the cell allowing them to be detected by the
host'simmune mechanisms. Thesupernatant from neuraminidase-treated tumour
cells, however, does not immunize mice against the tumour under conditions where
washed treated tumour cells induce a powerful immunity. The enzyme does not
therefore allow the escape ofantigens during the period ofincubation by increasing
the " leakiness " of the cell wall.
Cross reacting antigens
Neuraminidase is derived from bacterial cultures. It is not inconceivable that
contaminating bacterial antigens might adsorb to the tumour cell surface during
incubation and cross react with tumour antigens. Pre-exposure of the host mice
to neuraminidase provides no protection against tumour growth. This indicates
that the neuraminidase preparation used did not contain antigens which directly
cross reacted with the tumour. Heat lability studies show that the neuraminidase
preparation was inactivated at 600 C. in the presence of calcium ions. Similar
studies of receptor destroying enzyme (RDE) reveal that the active principle has
similar heat lability characteristics (Burnet and Stone, 1947). Further work is in
progressto characterize the active componentoftheenzymepreparationusedin the
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Modification of Host isoantigens
It could be argued that the enzyme acts on A2G strain isoantigens, modifying
them so that they cross react with the tumour. However, pre-exposure to
neuraminidase-treated A2G spleen cells affords no protection against tumour. It
would also have to be postulated that neuraminidase is carried across to the host
animal with the tumour cells. This would seem unlikely in view of the extensive
washing oftreated cells employed in this study.
Non-specific stimulation of the immune response
Sanford (1967) has shown that this explanation is unlikely by demonstrating
that the addition ofFreund's adjuvant to injected tumour cells induced no evidence
of immunity to tumour growth. She also revealed that treatment of mice with
neuraminidase did not affect first set skin graft rejection.
Modification of tumour cell periphery
In the present studyneuraminidase-treatedtumour cellsgrewinhydrocortisone-
treated mice, demonstrating that the inoculated tumour cells were viable and
capable of growing in the absence of an effective immune response. This study
incidentally supports Wheatley and Easty's observation (1964) that tumour
development is slowed in hydrocortisone-treated animals. Dye exclusion studies
have also suggested that tumour cell viability is not affected by neuraminidase.
Studies of the adsorption of agglutinating antisera indicate that neuraminidase
treatment does not affect antigen-antibody interactions in an agglutination system.
This would also indicate that neuraminidase does not affect the antigens per se,
either quantitatively or qualitatively. In other words, it probably operates at the
afferent end of the immunological arc. Its effect must therefore be directed to
the periphery of the intact living tumour cell. Exposure to neuraminidase seems
to allow previously undetected cell wall antigens to be detected by the host's
immune mechanisms.
Neuraminidase acts on sialomucinsbyhydrolytic cleavage of 0-glycoside bonds
between the keto group of sialic (N-acetyl neuraminic) acid and its underlying
amino-sugar (Gottschalk, 1957). Thus the unmasking of tumour antigens is
associated with removal of the terminal sialic acid moiety from cell wall sialomu-
cins. The free carboxyl groups of the sialic acid moiety are electronegative and
make a substantial contribution to the negative charge at the periphery of many
mammalian cell types. Thus theunmasking oftumour antigens by neuraminidase
isa ssociated with a fall in electronegative charge at the cell periphery (Currie,
1967). This phenomenon could provide two possible explanations of the masking
of antigens by cell wall sialomucins and for the effect of neuraminidase.
(a) As previously postulated (Currie, 1967) the high net negative charge at the
cell periphery could directly inhibit the approach of negatively charged lymphoid
cells by Coulomb forces. By reducing this charge neuraminidase would allow
more stable intercellular contacts to occur and thus initiate the cellular component
of the immune response.
(b) The sialomucins could mask antigens from detection by steric hindrance
alone. Treatment with neuraminidase would reduce the negative charges at the
free ends of the mucoprotein molecules and thus, as suggested by Gottschalk
(1960), allow a rearrangement of the tertiary structure of the polypeptide compo-
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nent of these molecules. This rearrangement might abolish any masking due to
steric hindrance.
Studies ofthe effects ofneuraminidase on the surface charge oftumour cells and
spleen cells have so far lent support to the former hypothesis (Currie, 1967).
The effect of neuraminidase on the immunogenicity of tumours has so far only
been described in the Ehrlich, the Landschiitz and the TA3 ascites tumours.
These are non-specific transplantable tumours whose antigenicity is probably
derived from histocompatibility antigens of the mouse of origin of each tumour.
Further studies of autochthonous tumours are in progress to determine whether
tumour-specific antigens are masked by cell wall sialomucins.
Gasic and Beydak (1961) have demonstrated that many tumour cells possess an
acidic mucoprotein coat and Gasic and Gasic (1962) have disrupted this layer with
neuraminidase, demonstrating the presence of sialic acid. Studies of cell surface
charge have also revealed that many animal tumours possess a high net negative
charge (Ruhenstroth-Bauer et al., 1962) which can be attributed wholly or in part to
the presence of sialic acid in the cell periphery. Sialic acid containing muco-
proteins are also present in the peritrophoblastic " fibrinoid " material. A recent
study of the effects ofneuraminidase on the immunogenicity of mouse trophoblast
(Currie, van Doorninck and Bagshawe, 1968, unpublished data) has suggested that
the histocompatibility antigens on mouse trophoblast are masked by pericellular
sialomucins. Disruption of pericellular sialomucins around trophoblast and some
experimental tumours is thus associated with the " unmasking " of previously
hidden antigenicity and suggests that this form of specific afferent inhibition of
the immune response (Billingham, Brent and Medawar, 1956) may play an impor-
tant role in both foeto-maternal and tumour-host interactions.
Neuraminidase appears to be a valuable tool for the exploration of the role of
the cell periphery in the immunology of such interactions.
SUMMARY
The mode ofactioin ofneuraminidase on the immunogenicity ofthe Landschiitz
ascites tumour has been investigated. When neuraminidase-treated Landschhtz
ascites tumour cells were injected into A2G male mice no tumour growth occurred
and a powerful tumour immunity ensued. Circulating anti-tumour agglutinins
appeared in the peripheral blood and when rechallenged with untreated tumour,
the mice remained tumour free. Treament of the recipient mice with hydrocor-
tisone abolished this effect. It was also abolished by heating the neuraminidase
preparation to 60( C. for 30 minutes in the presence of calcium ions. The neura-
minidase preparation used did not contain cross-reacting antigens and it did not
induce cross reaction of host cell isoantigens with the tumour. The supernatant
from treated tumour cells was not immunogenic indicating that antigenic molecules
were not released from the tumnour cell surface by treatment with this enzyme.
Cell viability was not affected by neuraminidase. The weight ofevidence implies
that this enzyme works by a direct effect on the cell periphery.
'l'he role of cell wall sialomucins in the masking of antigens and the action of
neuraminidase on this mechanism are discussed.
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